Background: Continuous positive airway pressure (CPAP) is the standard treatment for obstructive sleep apnea (OSA) but it is often cumbersome so that adherence to CPAP therapy is limited. Objectives: We evaluated adherence to CPAP therapy after an additional educative intervention in OSA patients after a longer treatment period. Methods: A short patient information program covering many aspects of symptoms, consequences and treatment of OSA was created, and standardized information sessions were developed to be given by an experienced sleep physician to >6,000 participants of patient support group meetings throughout Germany. They also received a booklet containing the essential information of the lectures. Of the 526 randomly selected members of these support groups receiving the anonymized questionnaire by mail, 475 CPAP patients sent the questionnaire back. Of these CPAP patients, 243 participated in a lecture und and had received a booklet (information group) and 232 CPAP patients had not attended a lecture (control group). Results: In the information group, a significantly higher daily usage of CPAP devices (6.9 ± 0.9 h/day) was reported compared with the control group (5.7 ± 1.3 h/day; p < 0.001). Furthermore, the score in the Epworth Sleepiness Scale (ESS) was found to be significantly lower in the information group (median ESS = 6, interquartile range, IQR, 4–8 vs. median = 11, IQR 8–13; p < 0.001). Conclusions: Patients who attended our short information program showed a higher daily usage and a lower subjective daytime sleepiness. These results suggest that patients on CPAP therapy may benefit from education even after a longer treatment period.

Keywords:
Continuous positive airway pressure, Obstructive sleep apnea syndrome, Patient education, Treatment adherence
1.
McNicholas WT, Bonsigore MR: Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29:156–178.
2.
Flemons WW, Tsai W: Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S750–S756.
3.
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235.
4.
Sullivan CE, Issa FG, Berthon-Jones M, Eves L: Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;i:862–865.
5.
Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ: Continuous positive airway pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;3:CD001106.
6.
Gordon P, Sanders MH: Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome. Thorax 2005;60:68–75.
7.
Krieger J, Kurtz D, Petiau C, Sforza E, Trautmann D: Long-term compliance with CPAP therapy in obstructive sleep apnea patients and in snorers. Sleep 1996;19:136–143.
8.
Sin DD, Mayers I, Man GC, Pawluk L: Long-term compliance rates to continuous positive airway pressure in obstructive sleep apnea: a population-based study. Chest 2002;121:430–435.
9.
Rauscher H, Formanek D, Popp W, Zwick H: Self-reported vs. measured compliance with nasal CPAP for obstructive sleep apnea. Chest 1993;103:1675–1680.
10.
Engleman HM, Martin SE, Douglas NJ: Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax 1994;49:263–266.
11.
Reeves-Hoche MK, Meck R, Zwillich CW: Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994;149:149–154.
12.
Pepin JL, Krieger J, Rodenstein D, Cornette A, Sforza E, Delguste P, Deschaux C, Grillier V, Levy P: Effective compliance during the first 3 months of continuous positive airway pressure. A European prospective study of 121 patients. Am J Respir Crit Care Med 1999;160:1124–1129.
13.
Meurice JC, Dore P, Paquereau J, Neau JP, Ingrand P, Chavagnat JJ, Patte F: Predictive factors of long-term compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest 1994;105:429–433.
14.
Richard W, Venker J, den Herder C, Kox D, van den Berg B, Laman M, van Tinteren H, de Vries N: Acceptance and long-term compliance of nCPAP in obstructive sleep apnea. Eur Arch Otorhinolaryngol 2007;264:1081–1086.
15.
Stepnowsky CJ, Dimsdale JE: Dose-response relationship between CPAP compliance and measures of sleep apnea severity. Sleep Med 2002;3:329–334.
16.
Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF: Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:887–895.
17.
McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ: Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:1108–1114.
18.
Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ: Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? Am J Respir Crit Care Med 1999;159:1096–1100.
19.
Hui DS, Chan JK, Choy DK, Ko FW, Li TS, Leung RC, Lai CK: Effects of augmented continuous positive airway pressure education and support on compliance and outcome in a Chinese population. Chest 2000;117:1410–1416.
20.
Palmer S, Selvaraj S, Dunn C, Osman LM, Cairns J, Franklin D, Hulks G, Godden DJ: Annual review of patients with sleep apnea/hypopnea syndrome – a pragmatic randomised trial of nurse home visit versus consultant clinic review. Sleep Med 2004;5:61–65.
21.
Chervin RD, Theut S, Bassetti C, Aldrich MS: Compliance with nasal CPAP can be improved by simple interventions. Sleep 1997;20:284–289.
22.
Likar LL, Panciera TM, Erickson AD, Rounds S: Group education sessions and compliance with nasal CPAP therapy. Chest 1997;111:1273–1277.
23.
Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J Jr, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS: Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 2006;29:375–380.
24.
Bloch KE, Schoch OD, Zhang JN, Russi EW: German version of the Epworth Sleepiness Scale. Respiration 1999;66:440–447.
25.
Jean Wiese H, Boethel C, Phillips B, Wilson JF, Peters J, Viggiano T: CPAP compliance: video education may help! Sleep Med 2005;6:171–174.
26.
Richards D, Bartlett DJ, Wong K, Malouff J, Grunstein RR: Increased adherence to CPAP with a group cognitive behavioral treatment intervention: a randomized trial. Sleep 2007;30:635–640.
27.
Russo-Magno P, O’Brien A, Panciera T, Rounds S: Compliance with CPAP therapy in older men with obstructive sleep apnea. J Am Geriatr Soc 2001;49:1205–1211.
28.
Krieger J, Kurtz D: Objective measurement of compliance with nasal CPAP treatment for obstructive sleep apnoea syndrome. Eur Respir J 1988;1:436–438.
29.
Fletcher EC, Luckett RA: The effect of positive reinforcement on hourly compliance in nasal continuous positive airway pressure users with obstructive sleep apnea. Am Rev Respir Dis 1991;143:936–941.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.